Finasteride vs Minoxidil: What the Evidence Shows About Each Hair Loss Medication

Androgenetic alopecia, the most common form of progressive hair thinning, prompts many individuals to research medication options. Two drugs—finasteride and minoxidil—are frequently discussed, and searches comparing finasteride vs minoxidil reflect a desire to understand which option might fit a particular situation. The short answer is that they work through entirely different mechanisms, target different parts of the hair-loss process, and carry distinct profiles of evidence, response variation, and reported side effects. One is not simply a substitute for the other.

This page summarizes what published clinical trials and regulatory sources report about each medication, where they overlap or diverge, and the honest limits of each approach. Dr. Charles Pereyra, a board-certified emergency physician and member of the International Society of Hair Restoration Surgery, reviews medication candidacy during the Follicular Health Assessment at Springs Rejuvenation Hair clinics in Miami, Los Angeles, Austin, Atlanta, and New York.

How finasteride and minoxidil work (two different mechanisms)

Finasteride is a type II 5-alpha-reductase inhibitor. The enzyme 5-alpha-reductase converts testosterone into dihydrotestosterone (DHT), the androgen that miniaturizes genetically susceptible hair follicles in androgenetic alopecia. By inhibiting that enzyme, finasteride reduces DHT levels in the scalp and serum by approximately 60 to 70 percent, as reported in the context of early trials (Kaufman, 1998). The drug does not block testosterone itself; in fact, serum testosterone may rise slightly when less is converted to DHT, addressing the common question of whether finasteride increases or lowers testosterone—it typically does not lower it. Finasteride is taken orally as a daily tablet and is FDA-approved at a 1-milligram dose for male pattern hair loss.

Minoxidil operates through a completely different pathway. It is a potassium-channel opener and vasodilator originally developed for hypertension. Applied to the scalp, minoxidil appears to prolong the anagen (growth) phase of the hair cycle, shorten the telogen (resting) phase, and may increase blood flow to follicles. Importantly, minoxidil does not block DHT. The drug must be activated within the hair follicle by an enzyme called sulfotransferase, and individuals vary widely in the activity of that enzyme (Roberts, 2014). This variation helps explain why minoxidil does not work for everyone—a meaningful share of users are biochemical non-responders. Minoxidil is available as a topical solution or foam in 2% and 5% concentrations, FDA-approved for over-the-counter use in men and women, and is also prescribed off-label as a low-dose oral tablet.

Because the mechanisms are so different, some individuals use both medications together. Finasteride addresses the hormonal driver of miniaturization; minoxidil attempts to stimulate existing follicles regardless of DHT levels. Whether to use minoxidil without finasteride, or finasteride without minoxidil, depends on individual goals, side-effect tolerance, and the degree to which DHT reduction is considered necessary for that person's pattern of loss.

What the clinical trials show

The pivotal trial for finasteride 1 milligram was a two-year randomized, placebo-controlled study involving men with androgenetic alopecia (Kaufman, 1998). Participants taking finasteride showed an increase in hair count compared to baseline, while those on placebo experienced continued hair loss. Investigator assessments and patient self-assessments both favored the finasteride group. The trial established that finasteride can slow progression and, in many cases, produce regrowth of hair in men with androgenetic alopecia. Individual responses varied.

For minoxidil, a landmark trial compared 5% topical minoxidil, 2% minoxidil, and placebo over 48 weeks in men with androgenetic alopecia (Olsen, 2002). The 5% formulation produced significantly greater increases in hair count than the 2% version or placebo, and both active concentrations outperformed placebo. As with finasteride, not all participants responded equally, and a subset experienced minimal or no benefit.

A systematic review and meta-analysis pooled data from multiple randomized controlled trials of finasteride and minoxidil (Adil & Godwin, 2017). The authors concluded that both medications demonstrate efficacy above placebo in androgenetic alopecia, and that combination therapy may yield additive effects. More recently, a network meta-analysis attempted to rank the relative efficacy of various medications and dosages (Gupta, 2022). That analysis suggested a ranking order of dutasteride 0.5 milligram, finasteride 5 milligram, oral minoxidil 5 milligram, finasteride 1 milligram, and topical minoxidil formulations lower on the list. It is important to understand this as a relative ranking derived from indirect comparisons across studies with different designs, populations, and follow-up periods. Dutasteride, for example, is a dual 5-alpha-reductase inhibitor (types I and II) and is not FDA-approved for hair loss in the United States; its use in this context is off-label. The ranking does not mean any one option is universally appropriate or that higher-ranked agents are without trade-offs in side effects or regulatory status.

The evidence base supports the statement that finasteride and minoxidil both work in the sense that randomized trials document hair-count increases and slowing of progression compared to placebo. The degree of response, however, varies widely among individuals, and neither medication works for everyone.

Finasteride vs minoxidil at a glance

Side effects and the finasteride debate: an honest summary

No medication is free of side effects, and both finasteride and minoxidil have reported adverse events. The finasteride side-effect profile has generated particular debate, and an evidence-based discussion requires presenting both the trial data and the post-marketing observations.

The FDA-approved label for finasteride lists sexual side effects, including decreased libido, erectile dysfunction, and ejaculation disorders. In the pivotal trials, these events were reported by a small percentage of participants, and in many cases the symptoms resolved even with continued use of the drug (Kaufman, 1998). The incidence on finasteride was low and only modestly higher than on placebo. However, post-marketing case series and pharmacovigilance reports have documented persistent sexual, cognitive, and mood-related symptoms in a subset of men who took finasteride, in some instances lasting well beyond discontinuation of the drug (Irwig, 2022). Dr. Irwig has argued that routine pharmacovigilance mechanisms failed to capture the true scope of persistent side effects because clinical trials were not designed to assess long-term outcomes after stopping the medication. Additional studies have raised signals linking finasteride to mood disturbances and, in some analyses, suicidal ideation (Baldessarini & Pompili, 2021). Regulatory agencies in several countries have updated labeling to reflect these concerns.

In 2025, the U.S. FDA issued an alert regarding compounded topical finasteride products, noting that no topical finasteride formulation is FDA-approved, that systemic absorption can occur, and that individuals who are or may become pregnant should not handle crushed or broken tablets or compounded topical preparations due to risk of fetal harm (FDA, 2025). This underscores that even topical application is not without systemic exposure.

The clinical reality is that large randomized trials report low rates of side effects that often resolve, while case series and regulatory pharmacovigilance highlight a minority of individuals who experience significant, and in some cases persistent, adverse effects. Both data sets are part of the evidence. The decision to use finasteride involves weighing potential hair-related benefits against these risks in the context of an individual's medical history, and it is a decision that belongs to the patient in consultation with a physician. Sources such as MedlinePlus (NIH) provide additional context on finasteride's risks and contraindications.

Minoxidil's side-effect profile is different. Topical minoxidil commonly causes scalp irritation, dryness, or flaking, particularly with the solution formulation (the foam is often better tolerated). Unwanted hair growth on the face or other areas (hypertrichosis) can occur, especially in women using higher concentrations. Serious cardiovascular effects are rare with topical use but have been reported. Oral minoxidil, when used off-label for hair loss at low doses, produces hypertrichosis in a large proportion of users (Vañó-Galván, 2021). That multicenter study of 1,404 patients found hypertrichosis to be the most common adverse event, while cardiovascular effects such as peripheral edema, palpitations, and blood-pressure changes were uncommon but documented. The MedlinePlus drug information page for minoxidil notes that individuals with certain heart conditions should use the medication with caution.

It is also worth noting that dutasteride, sometimes discussed as an alternative to finasteride, inhibits both type I and type II 5-alpha-reductase and lowers DHT more completely than finasteride. The Gupta network meta-analysis (2022) ranked dutasteride 0.5 milligram as relatively more effective than finasteride 1 milligram. However, dutasteride is not FDA-approved for hair loss and carries a similar or potentially broader side-effect profile, including sexual and mood-related concerns. Its use for androgenetic alopecia is off-label.

Non-responders, combination use and stopping

A key question many individuals ask is why a medication might not work for them. For minoxidil, enzyme activity provides a biochemical explanation: the drug must be converted by sulfotransferase in the hair follicle to its active form, and some people have low activity of that enzyme (Roberts, 2014). These individuals are non-responders regardless of dose or formulation. There is no widely available clinical test to predict sulfotransferase activity before starting therapy, so response is typically judged after several months of use.

For finasteride, non-response is less well understood. Even with significant DHT reduction, some men experience continued miniaturization, suggesting that other pathways or genetic factors may contribute to their hair loss. The degree of response also depends on the stage of miniaturization at the time therapy begins; follicles that are severely miniaturized or fully dormant are unlikely to recover.

Because finasteride and minoxidil work through different mechanisms, combination therapy is common. Clinical evidence suggests that using both together may produce additive effects (Adil & Godwin, 2017), though individual responses still vary. Some individuals choose to use minoxidil without finasteride, particularly if they wish to avoid DHT suppression or have concerns about finasteride's side-effect profile. Conversely, finasteride can be used without minoxidil, though it does not provide the direct follicle-stimulating effect that minoxidil may offer. The choice often depends on goals, tolerance, and whether DHT reduction is considered a priority.

An important limitation of both medications is that stopping either one leads to reversal of any gains over the following months. Hair follicles that were maintained or regrown under the influence of the drug will typically resume miniaturization once the medication is withdrawn. This means that both finasteride and minoxidil require indefinite use to sustain results, and neither represents a one-time intervention.

Where medication fits alongside hair restoration surgery

Hair restoration surgery, such as Follicular Unit Excision (FUE), transplants hair follicles from a genetically stable donor zone (typically the back and sides of the scalp) to areas of thinning or baldness. Those transplanted follicles retain their original characteristics and are not subject to DHT-driven miniaturization, which is why results from a well-performed procedure can be durable over time. However, the procedure does not stop the underlying process of androgenetic alopecia in the native, non-transplanted hair.

Many individuals who undergo hair restoration surgery are counseled to consider medication—finasteride, minoxidil, or both—to help protect remaining native hair. The American Academy of Dermatology notes that androgenetic alopecia is a progressive condition and that medical therapy may help preserve existing hair density (AAD). Whether to use medication after a transplant is a individual decision made in consultation with the treating physician. Some people prefer to address specific areas surgically and accept gradual thinning elsewhere; others choose to combine surgical restoration with ongoing medication to slow further loss.

Dr. Pereyra performs Micrograft FUE procedures himself and reviews both surgical and non-surgical options during the Follicular Health Assessment. That consultation includes a discussion of medication candidacy, realistic timelines, and how different approaches might fit into a long-term plan. The goal is to provide enough information for each individual to make an informed choice based on their own priorities and medical context.

Individuals interested in learning more about their options may schedule a Follicular Health Assessment with Dr. Pereyra at Springs Rejuvenation Hair in Miami, Los Angeles, Austin, Atlanta, or New York by calling (888) 503-4482.

Medical disclaimer: Stem cell and exosome therapy is not an FDA approved therapy and is considered to be in the experimental stages; it is not FDA approved to treat any disease. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. This page is educational and is not medical advice; always consult a qualified physician. Written and reviewed for medical accuracy by Dr. Charles Pereyra, MD, Medical Director, Springs Rejuvenation Hair.